Disclosure: We may have a financial affiliation with some entities featured on this site. Rankings are editorial; see our methodology.
Educational content — not medical advice.
Update chip
What changed: FDA has publicly treated major semaglutide and tirzepatide injection shortages as resolved and, in April 2026 guidance updates, restated how 503A and 503B compounding limits apply when products are commercially available — including examples involving add-in APIs such as vitamin B12.
Why this story belongs on a ranking magazine
Telehealth Ranker compares programs, not prescriptions. But the regulatory backdrop shapes what those programs can advertise, ship, and promise. Shoppers reading Trustpilot threads about compounded sema” or “compounded tirz” need context: a five-star support experience does not rewrite federal compounding law, and a polished landing page does not equal FDA approval of a compounded copy.
Shortage resolved ≠ compounding banned in every case
FDA’s multi-year timeline (publicly summarized on the agency’s drug-alert page) tracks a shift from shortage-era flexibility toward ordinary commercial-availability rules:
- When a drug is on the shortage list, certain compounding pathways tied to shortage status are more available.
- When FDA determines a shortage is resolved, those shortage-dependent conditions narrow.
- Under 503A (state-licensed pharmacy / physician compounding), compounded products generally must be for an individual patient pursuant to a prescription, and compounders face limits on making drugs that are essentially copies of commercially available products regularly or in inordinate amounts.
- Under 503B (outsourcing facilities), compounding from bulk drug substances is restricted unless the substance is on the 503B bulks list or the drug is on the shortage list at the relevant times. FDA has stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or the drug shortage list (per the agencys April 2026 clarification block).
None of that is a bedside instruction. It is the landscape patients hear about when programs change menus, pause compounded offers, or emphasize brand-name pathways.
The “essentially a copy” idea — in plain language
FDAs April 1, 2026 clarification emphasizes that a compounded product can be treated as essentially a copy when it uses the same API(s) at the same, similar, or easily substitutable strength and the same route of administration as a commercially available product — unless a prescriber documents that a change produces a significant difference for an identified individual patient.
The agency also illustrated how combining an API such as semaglutide with another API (for example, vitamin B12) can still be analyzed as essentially a copy in some circumstances when strengths and route line up with commercial products. Marketing that implies a B12 combo is automatically a lawful, routinely mass-produced substitute for a brand GLP-1 is the kind of claim shoppers should read skeptically.
FDA further noted limited enforcement discretion language around very small monthly copy volumes in certain contexts details that matter to compounders and counsel, not to DIY dosing. Patients should ask clinicians and pharmacies how their prescription is justified, not try to self-apply 503A math.
What telehealth shoppers can usefully ask
Use these as educational prompts for a licensed clinician or program care team not as a checklist that “proves” a site is safe:
- Is the medication FDA-approved brand, or compounded?
- Which pharmacy fills it (503A pharmacy vs. 503B outsourcing facility), and is that named in writing?
- If compounded, what clinical reason is documented for this patient versus the commercial product?
- How are membership fees separated from medication costs, and what happens if supply or formulation options change mid-plan?
- What monitoring and follow-up are included if side effects appear?
Programs in our Wave 1 Top 10 telehealth weight-loss ranking are scored heavily on Trustpilot and Google experience signals plus pricing clarity and access model — not on whether they “beat the FDA.” Regulatory context belongs in news and footnotes; stars belong in review chips. Where compounded options are discussed: compounded medications are not FDA-approved.
How this intersects with rankings
Our methodology keeps review platforms primary because they capture operational friction cancellations, shipping, billing — that often spikes when formularies and pharmacy partners shift after policy changes. A brand that communicates supply changes clearly may keep stronger recent review themes than one that surprises members with mid-plan swaps.
Wave 1’s numbered Top 10 is live under that methodology. Affiliations do not guarantee position. Google review cells remain TBD until live verification; Trustpilot figures are research snapshots — Mod/ops should re-verify on publish day.